The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for nasopharyngeal carcinoma (NPC) merged T4N0–2 and T1–4N3 to create stage IVa. In the present study, we aimed to assess the difference in clinical outcomes and patterns of failure between 8th AJCC T4N0–2 and T1–4N3 NPC patients treated with intensity-modulated radiotherapy (IMRT).
We included 3107 patients with stage IVa NPC disease (1871 with T4N0–2 and 1236 with T1–4N3) according to the 8th AJCC staging system. Overall survival (OS) was the primary endpoint. The clinical outcomes between T4N0–2 and T1–4N3 patients were compared.
T1–4N3 patients had significantly worse 3-year OS (84.1% vs. 89.2%; p < 0.001) and distant metastasis–free survival (DMFS; 78.3% vs. 85.9%; p < 0.001), but better local relapse–free survival (LRFS; 94.9% vs. 92.2%; p = 0.003), as compared with T4N0–2 patients. Multivariate analysis showed that T1–4N3 was still an independent adverse prognostic factor for both DMFS (hazard ratio [HR] = 1.517, 95% confidence interval [CI] = 1.274–1.806, p < 0.001) and OS (HR = 1.315, 95% CI = 1.100–1.572, p = 0.003), whereas T4N0–2 was an independent adverse prognostic factor for LRFS (HR = 1.581, 95% CI = 1.158–2.158, p = 0.004).
In terms of the OS, T4N0–2 patients had better prognosis compared with T1–4N3 patients, and the patterns of failure differed between T4N0–2 and T1–4N3 patients. We believe that future modifications of the AJCC/UICC staging system should separate T4N0–2 from T1–4N3.
• In nasopharyngeal carcinoma, T4N0–2 patients tended to develop local relapse, whereas T1–4N3 patients were more likely to develop distant metastasis.
• In terms of overall survival, T4N0–2 patients had better prognosis than T1–4N3 patients.
• T4N0–2 should be separated from T1–4N3 in the UICC/AJCC staging system.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
American Joint Committee on Cancer/Union for International Cancer Control
Distant metastasis–free survival
Gross tumor volume
Local relapse–free survival
Magnetic resonance imaging
Positron emission tomography CT
Regional relapse–free survival
Single photon emission computed tomography
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Amin MB, American Joint Committee on Cancer (2016) AJCC cancer staging manual, 8th edn. Springer, New York
Pan JJ, Ng WT, Zong JF et al (2016) Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122:546–558
Tang LL, Chen YP, Mao YP et al (2017) Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw 15:913–919
OuYang P-Y, Xiao Y, You K-Y et al (2017) Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 72:65–72
Zeng L, Tian YM, Sun XM et al (2014) Intensity-modulated radiotherapy for stage IVA/IVB nasopharyngeal carcinoma: clinical outcomes and patterns of failure in an endemic area in China. Strahlenther Onkol 190:993–1000
Huang CL, Sun ZQ, Guo R et al (2019) Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2019.01.007
Guo R, Tang LL, Mao YP et al (2019) Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 125:79–89
Lee AW, Lin JC, Ng WT (2012) Current management of nasopharyngeal cancer. Semin Radiat Oncol 22:233–244
Mao YP, Tang LL, Chen L et al (2016) Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer 35:103
Kaplan EL, Meier P (1958) Nonparameric estimation from incomplete observation. J Am Stat Assoc 53:457–481
Lee AW, Ng WT, Chan LK et al (2012) The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol 48:1007–1013
Zhang L, Yang L, Li JJ, Sun L (2012) Potential use of nucleic acid-based agents in the sensitization of nasopharyngeal carcinoma to radiotherapy. Cancer Lett 323:1–10
Chen YP, Tang LL, Yang Q et al (2018) Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 24:1824–1833
Agulnik M, Siu LL (2005) State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer 92:799–806
Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ (2000) Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48:329–337
Chen YP, Wang ZX, Chen L et al (2015) A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 26:205–211
Lai SZ, Li WF, Chen L et al (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80:661–668
Peng G, Wang T, Yang KY et al (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104:286–293
Han L, Lin SJ, Pan JJ et al (2010) Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 29:145–150
Lin JC, Wang WY, Chen KY et al (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461–2470
Leung SF, Chan KC, Ma BB et al (2014) Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 25:1204–1208
Jin YN, Yao JJ, Zhang F et al (2017) Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? J Cancer 8:976–982
The scientific guarantor of this publication is Ling-Long Tang from Sun Yat-sen University Cancer Center (Guangzhou, China).
Conflict of interest
The authors declare that they have no conflict of interest.
Statistics and biometry
One of the authors, Ai-Hua Lin, who is from the Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University (Guangzhou, China), has significant statistical expertise.
Written informed consent was waived by the Institutional Review Board.
Institutional Review Board approval was obtained.
• Diagnostic or prognostic study
• Performed at one institution
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Huang, C., Guo, R., Li, J. et al. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. Eur Radiol 30, 816–822 (2020) doi:10.1007/s00330-019-06500-5
- Treatment failure
- Nasopharyngeal carcinoma
- Intensity-modulated radiotherapy